PKD1P1 and B-cell non-Hodgkin lymphoma: Recently, a novel fusion protein, the anti-huCD20(hγ1)-IL2no-alpha immunocytokine (IC), was presented as a promising therapeutic alternative, mostly for relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients, considering currently approved therapies.<h4>Methods</h4>Three Chinese hamster ovary clones (K1 strain) producing the anti-huCD20(hγ1)-IL2no-alpha IC were generated and adapted to serum-free suspension culture.